GLP-1 Market Shifts Amid Patent Expiries and Trial Setbacks
The GLP‑1 landscape is undergoing a profound transformation as commercial realities collide with evolving clinical data. Early in 2026, Novo Nordisk issued a si...
May 13, 2026
0 59
GLP-1 & Metabolic Health — Latest Articles
In-depth reporting on GLP‑1 therapies, metabolic health, obesity treatment, and cardiometabolic research.
Showing 25 to 27 of 27 articles
Tirzepatide’s CV findings and Medicare’s GLP‑1 Bridge
Lede Two developments this year are reshaping how clinicians, patients, and policymakers view next‑generation incretin therapies: the full report of the SURPASS...
May 11, 2026
0 48
Oral Wegovy, higher‑dose semaglutide, and compounding limits reshape GLP‑1 market
Lede Two regulatory actions this winter — the FDA's approval of an oral Wegovy pill and a new higher‑dose semaglutide injection — plus a proposed FDA curtailing...
May 10, 2026
0 54
Join the mailing list
Get new posts from GLP-1 & Metabolic Health News
Be the first to know when fresh articles are published.